Angina Pectoris Drugs Market Size, Share and Growth Outlook, 2026

Angina Pectoris Drugs Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Angina Pectoris Drugs Market size is forecast to increase from $12.64 Billion in 2026 to $20.61 Billion in 2034 at a CAGR of 6.3% between 2026 and 2034.

The Angina Pectoris Drugs market report provides detailed analysis and outlook of Angina Pectoris Drugs segments including By Drug Class (Beta Blockers, Calcium Channel Blockers, Nitrates & Nitrites, Anti-platelet Agents, Anticoagulants, ACE Inhibitors, Metabolic Agents), By Type of Angina (Stable Angina, Unstable Angina, Variant, Microvascular Angina), By Route of Administration (Oral, Injectable, Topical/Transdermal, Sublingual/Buccal), By End User (Hospitals & Clinics, Homecare Settings, Diagnostic Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Angina Pectoris Drugs Industry Overview

Advancements in Chronic Stable Angina Drug Development

The angina pectoris drugs industry is witnessing significant innovation as pharmaceutical companies focus on developing therapies that improve symptom management and long-term cardiovascular outcomes. A notable development is the successful Series A financing secured by Auxilius Pharma to accelerate the clinical advancement of AUX-001, a once-daily extended-release formulation of nicorandil for chronic stable angina pectoris (CSAP). Nicorandil is recognized for its dual mechanism of action, promoting dilation of both macrovascular and microvascular coronary arteries to enhance myocardial blood flow and reduce ischemic episodes. While immediate-release nicorandil has established use across Europe and Asia, the development of an extended-release formulation aims to improve patient adherence and therapeutic consistency. Growing investment activity in cardiovascular therapeutics highlights continued demand for innovative anti-anginal drugs capable of addressing persistent unmet clinical needs in coronary artery disease management.

Regulatory Pathways Accelerating Market Expansion

Regulatory developments are playing a crucial role in supporting the introduction of novel angina therapies. Following positive pre-IND discussions, the U.S. FDA confirmed that AUX-001 qualifies for the streamlined 505(b)(2) regulatory pathway, enabling developers to leverage existing clinical evidence and potentially bypass Phase 2 studies. This approach significantly reduces development timelines and costs while facilitating faster access to new treatment options for patients with chronic stable angina. The increasing utilization of accelerated regulatory frameworks is encouraging pharmaceutical companies to invest in reformulations and differentiated cardiovascular therapies that can efficiently reach commercialization while addressing treatment gaps in the U.S. market.

Emerging Therapies and Advanced Diagnostic Support

The industry is also benefiting from advancements in gene therapy and cardiovascular diagnostics. Strategic leadership initiatives are accelerating the development of XC001, an investigational angiogenic gene therapy designed for patients with severe coronary artery disease and refractory angina pectoris who are no longer eligible for conventional revascularization procedures. By promoting therapeutic angiogenesis, the treatment seeks to improve myocardial perfusion in patients with limited treatment alternatives. In parallel, the adoption of advanced positron emission tomography myocardial perfusion imaging (PET MPI) agents is enhancing the diagnosis of myocardial ischemia associated with angina-inducing coronary artery disease. Featuring a practical 109-minute half-life that eliminates the need for on-site cyclotron infrastructure, these imaging agents provide superior diagnostic performance compared with traditional SPECT imaging. Additional reimbursement support through drug-specific billing pathways is further improving accessibility to advanced diagnostic evaluation and supporting precision-guided cardiovascular care.

Angina Pectoris Drugs Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Angina Pectoris Drugs market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- AstraZeneca PLC, Novartis AG, Pfizer Inc., Bayer AG, Johnson & Johnson, Merck & Co., Inc., Eli Lilly and Company, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim International GmbH. The Angina Pectoris Drugs market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Angina Pectoris Drugs industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Angina Pectoris Drugs Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Angina Pectoris Drugs companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Angina Pectoris Drugs markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Angina Pectoris Drugs Market Competitive Benchmarking and Company Analysis

Leading companies in Angina Pectoris Drugs industry include- AstraZeneca PLC, Novartis AG, Pfizer Inc., Bayer AG, Johnson & Johnson, Merck & Co., Inc., Eli Lilly and Company, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim International GmbH. The Angina Pectoris Drugs market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Angina Pectoris Drugs Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Angina Pectoris Drugs market remains one of the strongest-performing segments in the country.
The US Angina Pectoris Drugs Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Angina Pectoris Drugs market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Angina Pectoris Drugs industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Angina Pectoris Drugs markets

Canada's strong Angina Pectoris Drugs sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Angina Pectoris Drugs market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Angina Pectoris Drugs Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Angina Pectoris Drugs market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Angina Pectoris Drugs population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Angina Pectoris Drugs industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Angina Pectoris Drugs market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Angina Pectoris Drugs sales through 2034

France Angina Pectoris Drugs companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Angina Pectoris Drugs Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Angina Pectoris Drugs distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Angina Pectoris Drugs Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Angina Pectoris Drugs market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Angina Pectoris Drugs industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Angina Pectoris Drugs industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Angina Pectoris Drugs Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Angina Pectoris Drugs market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Angina Pectoris Drugs market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Angina Pectoris Drugs Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Angina Pectoris Drugs Market Segmentation

By Drug Class
Beta Blockers
Calcium Channel Blockers
Nitrates & Nitrites
Anti-platelet Agents
Anticoagulants
ACE Inhibitors
Metabolic Agents
By Type of Angina
Stable Angina
Unstable Angina
Variant
Microvascular Angina
By Route of Administration
Oral
Injectable
Topical/Transdermal
Sublingual/Buccal
By End User
Hospitals & Clinics
Homecare Settings
Diagnostic Centers

Top Companies in Angina Pectoris Drugs Industry

AstraZeneca PLC
Novartis AG
Pfizer Inc.
Bayer AG
Johnson & Johnson
Merck & Co., Inc.
Eli Lilly and Company
Abbott Laboratories
Sanofi S.A.
Boehringer Ingelheim International GmbH

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025